Skip to main
ILMN

Illumina (ILMN) Stock Forecast & Price Target

Illumina (ILMN) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 27%
Buy 33%
Hold 27%
Sell 7%
Strong Sell 7%

Bulls say

Illumina is currently well-positioned in the centralized model of the sequencing industry, and management continues to plan for innovation in the holistic workflow rather than just speed or price. They also maintain transparency with customers on the long-term roadmap, instilling confidence in their future prospects. With strategic pricing decisions and strong gross margins in their consumables segment, Illumina has a solid foundation for continued growth in the clinical market. Despite temporary challenges in the academic market, we expect Illumina's new product offerings and increasing demand for clinical applications to support eventual stability in academic demand. However, there are risks associated with Illumina's academic and China market, as well as potential competition in the future.

Bears say

Illumina is facing concerns about their quarterly expectations and instrument placements, as well as discounting on high-throughput instruments. However, their focus on capturing longer-term business and strong demand for their instruments from clinical customers indicate a hold on the clinical sequencing market. Overall, with their strong position in the clinical market and potential for sustained revenue growth, Illumina maintains a favorable risk/reward for investors.

Illumina (ILMN) has been analyzed by 15 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 33% recommend Buy, 27% suggest Holding, 7% advise Selling, and 7% predict a Strong Sell.

This aggregate rating is based on analysts' research of Illumina and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Illumina (ILMN) Forecast

Analysts have given Illumina (ILMN) a Buy based on their latest research and market trends.

According to 15 analysts, Illumina (ILMN) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $201.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $201.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Illumina (ILMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.